ReviewBritish journal of pharmacology2008
Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.
Review in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Taurine supplementation in fish meal-free diet improved growth, alleviated hypoxic-induced gill injury associating with CaAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- The application of breath-holding in sports: physiological effects, challenges, and future directions.European journal of applied physiology · 2025Review
- Insect Larvae as an Alternate Protein Source in Poultry Feed Improve the Performance and Meat Quality of Broilers.Animals : an open access journal from MDPI · 2024Article
- Six weeks of dynamic apnoeic training stimulates erythropoiesis but does not increase splenic volume.European journal of applied physiology · 2021Article
- Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events.Frontiers in physiology · 2020Article
- Erythropoietic responses to a series of repeated maximal dynamic and static apnoeas in elite and non-breath-hold divers.European journal of applied physiology · 2019Article
- 'Blood doping' from Armstrong to prehabilitation: manipulation of blood to improve performance in athletes and physiological reserve in patients.Extreme physiology & medicine · 2016Review
- Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.Endocrine reviews · 2014Review
- Drug abuse in athletes.Substance abuse and rehabilitation · 2014Review
- Article
- Erythropoietin.Cold Spring Harbor perspectives in medicine · 2013Review
- Performance-enhancing drugs.Pediatrics in review · 2012Review
- The evolving science of detection of 'blood doping'.British journal of pharmacology · 2012Review
- Drugs of abuse and the adolescent athlete.Italian journal of pediatrics · 2010Review
- Drugs in sport.British journal of pharmacology · 2008Article
- Drugs in sport: a scientist-athlete's perspective: from ambition to neurochemistry.British journal of pharmacology · 2008Review
- Performance-Enhancing Drug Use in Adolescence.American journal of lifestyle medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxygen is essential for life, and the body has developed an exquisite method to collect oxygen in the lungs and transport it to the tissues. Hb contained within red blood cells (RBCs), is the key oxygen-carrying component in blood, and levels of RBCs are tightly controlled according to demand for oxygen. The availability of oxygen plays a critical role in athletic performance, and agents that enhance oxygen delivery to tissues increase aerobic power. Early methods to increase oxygen delivery included training at altitude, and later, transfusion of packed RBCs. A breakthrough in understanding how RBC formation is controlled included the discovery of erythropoietin (Epo) and cloning of the EPO gene. Cloning of the EPO gene was followed by commercial development of recombinant human Epo (rHuEpo). Legitimate use of this and other agents that affect oxygen delivery is important in the treatment of anaemia (low Hb levels) in patients with chronic kidney disease or in cancer patients with chemotherapy-induced anaemia. However, competitive sports was affected by illicit use of rHuEpo to enhance performance. Testing methods for these agents resulted in a cat-and-mouse game, with testing labs attempting to detect the use of a drug or blood product to improve athletic performance (doping) and certain athletes developing methods to use the agents without being detected. This article examines the current methods to enhance aerobic performance and the methods to detect illicit use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.